Donald E Tsai
Overview
Explore the profile of Donald E Tsai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kushner C, Wang S, Tovanabutra N, Tsai D, Werth V, Payne A
JAMA Dermatol
. 2019 Oct;
155(12):1404-1409.
PMID: 31642878
Importance: Rituximab has emerged as a front-line therapy for pemphigus, but prognostic factors for achieving complete remission off therapy (CROT) with oral systemic agents remain unknown. Objectives: To describe rates...
12.
Nagle S, Shah N, Ganetsky A, Landsburg D, Nasta S, Mato A, et al.
Int J Hematol Oncol
. 2018 Oct;
6(4):113-121.
PMID: 30302232
Aim: To describe the long-term outcomes of patients with lymphoma in the CNS treated with rituximab, temozolomide and high-dose methotrexate without consolidation therapy. Patients & Methods: A retrospective cohort study...
13.
Debonera F, Nasta S, Martinez-Lage M, Schuster S, Tsai D
Int J Hematol Oncol
. 2018 Oct;
6(3):69-73.
PMID: 30302227
There is no consensus on the optimal therapy for primary CNS lymphoma. Conventional treatment modalities include chemotherapy and radiation therapy, which carry significant risks of morbidity and mortality. In systemic...
14.
Tsai D, Bagley S, Reshef R, Shaked A, Bloom R, Ahya V, et al.
Am J Hematol
. 2018 Apr;
93(7):874-881.
PMID: 29659047
Posttransplant lymphoproliferative disorder (PTLD) typically presents with either polymorphic or monomorphic histology. While both are the end result of immunosuppressive therapies, their origins are felt to be different with different...
15.
Nagle S, Reshef R, Tsai D
Clin Chest Med
. 2017 Nov;
38(4):771-783.
PMID: 29128025
Posttransplant lymphoproliferative disorders (PTLD) represent an immunosuppression-related lymphoid or plasmacytic proliferation that occur in the setting of solid organ transplant or allogeneic hematopoietic stem cell transplantation (HSCT). PTLD is a...
16.
Kremer B, Tsai D, Debonera F, Cohen P, Schuster S
Leuk Lymphoma
. 2017 Jul;
59(3):743-745.
PMID: 28695787
No abstract available.
17.
Paul T, Liu S, Chong E, Luger S, Porter D, Schuster S, et al.
Clin Lymphoma Myeloma Leuk
. 2015 Jul;
15(9):536-40.
PMID: 26141214
Background: High-dose melphalan with autologous stem cell support improves survival for patients with myeloma. For selected patients, we have been using a protocol of short hospitalization, discharging patients to home...
18.
Tsai D, Luskin M, Kremer B, Chung A, Arnoldi S, Paralkar V, et al.
Leuk Lymphoma
. 2014 Sep;
56(5):1530-2.
PMID: 25219594
No abstract available.
19.
Ellebrecht C, Choi E, Allman D, Tsai D, Wegener W, Goldenberg D, et al.
JAMA Dermatol
. 2014 Aug;
150(12):1331-5.
PMID: 25133328
IMPORTANCE B-cell depletion with the anti-CD20 antibody rituximab is highly effective for pemphigus vulgaris (PV) treatment. However,most patients experience relapse, and intravenous rituximab infusions are expensive. Therefore, cost-effective anti-CD20 therapies...
20.
Landsburg D, Stadtmauer E, Loren A, Goldstein S, Frey N, Nasta S, et al.
Am J Hematol
. 2013 May;
88(8):657-60.
PMID: 23640768
While the prognosis for older adults diagnosed with acute lymphoblastic leukemia (ALL) is frequently poor, long-term survival can be achieved in patients treated with curative intent. We reviewed the outcomes...